Report Detail

Pharma & Healthcare Global Adalimumab, Infliximab And Etanercept Biosimilars Market Outlook 2021

  • RnM4271962
  • |
  • 02 January, 2021
  • |
  • Global
  • |
  • 123 Pages
  • |
  • QYResearch
  • |
  • Pharma & Healthcare

1 Adalimumab, Infliximab And Etanercept Biosimilars Market Overview

  • 1.1 Product Overview and Scope of Adalimumab, Infliximab And Etanercept Biosimilars
  • 1.2 Adalimumab, Infliximab And Etanercept Biosimilars Segment by Product
    • 1.2.1 Global Adalimumab, Infliximab And Etanercept Biosimilars Sales Growth Rate Comparison by Product (2020-2026)
    • 1.2.2 Adalimumab Biosimilars
    • 1.2.3 Infliximab Biosimilars
    • 1.2.4 Etanercept Biosimilars
  • 1.3 Adalimumab, Infliximab And Etanercept Biosimilars Segment by End Users
    • 1.3.1 Adalimumab, Infliximab And Etanercept Biosimilars Sales Comparison by End Users: (2020-2026)
    • 1.3.2 Hospital Pharmacies
    • 1.3.3 Retail Pharmacies
    • 1.3.4 Online Pharmacies
  • 1.4 Global Adalimumab, Infliximab And Etanercept Biosimilars Market Size Estimates and Forecasts
    • 1.4.1 Global Adalimumab, Infliximab And Etanercept Biosimilars Revenue 2015-2026
    • 1.4.2 Global Adalimumab, Infliximab And Etanercept Biosimilars Sales 2015-2026
    • 1.4.3 Adalimumab, Infliximab And Etanercept Biosimilars Market Size by Region: 2020 Versus 2026

2 Global Adalimumab, Infliximab And Etanercept Biosimilars Market Competition by Manufacturers

  • 2.1 Global Adalimumab, Infliximab And Etanercept Biosimilars Sales Market Share by Manufacturers (2015-2020)
  • 2.2 Global Adalimumab, Infliximab And Etanercept Biosimilars Revenue Share by Manufacturers (2015-2020)
  • 2.3 Global Adalimumab, Infliximab And Etanercept Biosimilars Average Price by Manufacturers (2015-2020)
  • 2.4 Manufacturers Adalimumab, Infliximab And Etanercept Biosimilars Manufacturing Sites, Area Served, Product Type
  • 2.5 Adalimumab, Infliximab And Etanercept Biosimilars Market Competitive Situation and Trends
    • 2.5.1 Adalimumab, Infliximab And Etanercept Biosimilars Market Concentration Rate
    • 2.5.2 Global Top 5 and Top 10 Players Market Share by Revenue
    • 2.5.3 Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
  • 2.7 Primary Interviews with Key Adalimumab, Infliximab And Etanercept Biosimilars Players (Opinion Leaders)

3 Adalimumab, Infliximab And Etanercept Biosimilars Retrospective Market Scenario by Region

  • 3.1 Global Adalimumab, Infliximab And Etanercept Biosimilars Retrospective Market Scenario in Sales by Region: 2015-2020
  • 3.2 Global Adalimumab, Infliximab And Etanercept Biosimilars Retrospective Market Scenario in Revenue by Region: 2015-2020
  • 3.3 North America Adalimumab, Infliximab And Etanercept Biosimilars Market Facts & Figures by Country
    • 3.3.1 North America Adalimumab, Infliximab And Etanercept Biosimilars Sales by Country
    • 3.3.2 North America Adalimumab, Infliximab And Etanercept Biosimilars Sales by Country
    • 3.3.3 U.S.
    • 3.3.4 Canada
  • 3.4 Europe Adalimumab, Infliximab And Etanercept Biosimilars Market Facts & Figures by Country
    • 3.4.1 Europe Adalimumab, Infliximab And Etanercept Biosimilars Sales by Country
    • 3.4.2 Europe Adalimumab, Infliximab And Etanercept Biosimilars Sales by Country
    • 3.4.3 Germany
    • 3.4.4 France
    • 3.4.5 U.K.
    • 3.4.6 Italy
    • 3.4.7 Russia
  • 3.5 Asia Pacific Adalimumab, Infliximab And Etanercept Biosimilars Market Facts & Figures by Region
    • 3.5.1 Asia Pacific Adalimumab, Infliximab And Etanercept Biosimilars Sales by Region
    • 3.5.2 Asia Pacific Adalimumab, Infliximab And Etanercept Biosimilars Sales by Region
    • 3.5.3 China
    • 3.5.4 Japan
    • 3.5.5 South Korea
    • 3.5.6 India
    • 3.5.7 Australia
    • 3.5.8 Taiwan
    • 3.5.9 Indonesia
    • 3.5.10 Thailand
    • 3.5.11 Malaysia
    • 3.5.12 Philippines
    • 3.5.13 Vietnam
  • 3.6 Latin America Adalimumab, Infliximab And Etanercept Biosimilars Market Facts & Figures by Country
    • 3.6.1 Latin America Adalimumab, Infliximab And Etanercept Biosimilars Sales by Country
    • 3.6.2 Latin America Adalimumab, Infliximab And Etanercept Biosimilars Sales by Country
    • 3.6.3 Mexico
    • 3.6.4 Brazil
    • 3.6.5 Argentina
  • 3.7 Middle East and Africa Adalimumab, Infliximab And Etanercept Biosimilars Market Facts & Figures by Country
    • 3.7.1 Middle East and Africa Adalimumab, Infliximab And Etanercept Biosimilars Sales by Country
    • 3.7.2 Middle East and Africa Adalimumab, Infliximab And Etanercept Biosimilars Sales by Country
    • 3.7.3 Turkey
    • 3.7.4 Saudi Arabia
    • 3.7.5 U.A.E

4 Global Adalimumab, Infliximab And Etanercept Biosimilars Historic Market Analysis by Product

  • 4.1 Global Adalimumab, Infliximab And Etanercept Biosimilars Sales Market Share by Product (2015-2020)
  • 4.2 Global Adalimumab, Infliximab And Etanercept Biosimilars Revenue Market Share by Product (2015-2020)
  • 4.3 Global Adalimumab, Infliximab And Etanercept Biosimilars Price Market Share by Product (2015-2020)
  • 4.4 Global Adalimumab, Infliximab And Etanercept Biosimilars Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Global Adalimumab, Infliximab And Etanercept Biosimilars Historic Market Analysis by End Users

  • 5.1 Global Adalimumab, Infliximab And Etanercept Biosimilars Sales Market Share by End Users (2015-2020)
  • 5.2 Global Adalimumab, Infliximab And Etanercept Biosimilars Revenue Market Share by End Users (2015-2020)
  • 5.3 Global Adalimumab, Infliximab And Etanercept Biosimilars Price by End Users (2015-2020)

6 Company Profiles and Key Figures in Adalimumab, Infliximab And Etanercept Biosimilars Business

  • 6.1 Boehringer Ingelheim
    • 6.1.1 Corporation Information
    • 6.1.2 Boehringer Ingelheim Description, Business Overview
    • 6.1.3 Boehringer Ingelheim Adalimumab, Infliximab And Etanercept Biosimilars Sales, Revenue and Gross Margin (2015-2020)
    • 6.1.4 Boehringer Ingelheim Products Offered
    • 6.1.5 Boehringer Ingelheim Recent Development
  • 6.2 Abbvie
    • 6.2.1 Abbvie Corporation Information
    • 6.2.2 Abbvie Description, Business Overview
    • 6.2.3 Abbvie Adalimumab, Infliximab And Etanercept Biosimilars Sales, Revenue and Gross Margin (2015-2020)
    • 6.2.4 Abbvie Products Offered
    • 6.2.5 Abbvie Recent Development
  • 6.3 Cipla Ltd
    • 6.3.1 Cipla Ltd Corporation Information
    • 6.3.2 Cipla Ltd Description, Business Overview
    • 6.3.3 Cipla Ltd Adalimumab, Infliximab And Etanercept Biosimilars Sales, Revenue and Gross Margin (2015-2020)
    • 6.3.4 Cipla Ltd Products Offered
    • 6.3.5 Cipla Ltd Recent Development
  • 6.4 Hetero Drugs Limited
    • 6.4.1 Hetero Drugs Limited Corporation Information
    • 6.4.2 Hetero Drugs Limited Description, Business Overview
    • 6.4.3 Hetero Drugs Limited Adalimumab, Infliximab And Etanercept Biosimilars Sales, Revenue and Gross Margin (2015-2020)
    • 6.4.4 Hetero Drugs Limited Products Offered
    • 6.4.5 Hetero Drugs Limited Recent Development
  • 6.5 Pfizer
    • 6.5.1 Pfizer Corporation Information
    • 6.5.2 Pfizer Description, Business Overview
    • 6.5.3 Pfizer Adalimumab, Infliximab And Etanercept Biosimilars Sales, Revenue and Gross Margin (2015-2020)
    • 6.5.4 Pfizer Products Offered
    • 6.5.5 Pfizer Recent Development
  • 6.6 Novartis
    • 6.6.1 Novartis Corporation Information
    • 6.6.2 Novartis Description, Business Overview
    • 6.6.3 Novartis Adalimumab, Infliximab And Etanercept Biosimilars Sales, Revenue and Gross Margin (2015-2020)
    • 6.6.4 Novartis Products Offered
    • 6.6.5 Novartis Recent Development
  • 6.7 Samsung Bioepis(Samsung Biologics)
    • 6.6.1 Samsung Bioepis(Samsung Biologics) Corporation Information
    • 6.6.2 Samsung Bioepis(Samsung Biologics) Description, Business Overview
    • 6.6.3 Samsung Bioepis(Samsung Biologics) Adalimumab, Infliximab And Etanercept Biosimilars Sales, Revenue and Gross Margin (2015-2020)
    • 6.4.4 Samsung Bioepis(Samsung Biologics) Products Offered
    • 6.7.5 Samsung Bioepis(Samsung Biologics) Recent Development
  • 6.8 Amgen
    • 6.8.1 Amgen Corporation Information
    • 6.8.2 Amgen Description, Business Overview
    • 6.8.3 Amgen Adalimumab, Infliximab And Etanercept Biosimilars Sales, Revenue and Gross Margin (2015-2020)
    • 6.8.4 Amgen Products Offered
    • 6.8.5 Amgen Recent Development
  • 6.9 Celltrion Healthcare
    • 6.9.1 Celltrion Healthcare Corporation Information
    • 6.9.2 Celltrion Healthcare Description, Business Overview
    • 6.9.3 Celltrion Healthcare Adalimumab, Infliximab And Etanercept Biosimilars Sales, Revenue and Gross Margin (2015-2020)
    • 6.9.4 Celltrion Healthcare Products Offered
    • 6.9.5 Celltrion Healthcare Recent Development
  • 6.10 Mylan
    • 6.10.1 Mylan Corporation Information
    • 6.10.2 Mylan Description, Business Overview
    • 6.10.3 Mylan Adalimumab, Infliximab And Etanercept Biosimilars Sales, Revenue and Gross Margin (2015-2020)
    • 6.10.4 Mylan Products Offered
    • 6.10.5 Mylan Recent Development
  • 6.11 HETERO
    • 6.11.1 HETERO Corporation Information
    • 6.11.2 HETERO Adalimumab, Infliximab And Etanercept Biosimilars Description, Business Overview
    • 6.11.3 HETERO Adalimumab, Infliximab And Etanercept Biosimilars Sales, Revenue and Gross Margin (2015-2020)
    • 6.11.4 HETERO Products Offered
    • 6.11.5 HETERO Recent Development
  • 6.12 Glenmark Pharmaceuticals
    • 6.12.1 Glenmark Pharmaceuticals Corporation Information
    • 6.12.2 Glenmark Pharmaceuticals Adalimumab, Infliximab And Etanercept Biosimilars Description, Business Overview
    • 6.12.3 Glenmark Pharmaceuticals Adalimumab, Infliximab And Etanercept Biosimilars Sales, Revenue and Gross Margin (2015-2020)
    • 6.12.4 Glenmark Pharmaceuticals Products Offered
    • 6.12.5 Glenmark Pharmaceuticals Recent Development
  • 6.13 Emcure Pharmaceuticals
    • 6.13.1 Emcure Pharmaceuticals Corporation Information
    • 6.13.2 Emcure Pharmaceuticals Adalimumab, Infliximab And Etanercept Biosimilars Description, Business Overview
    • 6.13.3 Emcure Pharmaceuticals Adalimumab, Infliximab And Etanercept Biosimilars Sales, Revenue and Gross Margin (2015-2020)
    • 6.13.4 Emcure Pharmaceuticals Products Offered
    • 6.13.5 Emcure Pharmaceuticals Recent Development

7 Adalimumab, Infliximab And Etanercept Biosimilars Manufacturing Cost Analysis

  • 7.1 Adalimumab, Infliximab And Etanercept Biosimilars Key Raw Materials Analysis
    • 7.1.1 Key Raw Materials
    • 7.1.2 Key Raw Materials Price Trend
    • 7.1.3 Key Suppliers of Raw Materials
  • 7.2 Proportion of Manufacturing Cost Structure
  • 7.3 Manufacturing Process Analysis of Adalimumab, Infliximab And Etanercept Biosimilars
  • 7.4 Adalimumab, Infliximab And Etanercept Biosimilars Industrial Chain Analysis

8 Marketing Channel, Distributors and Customers

  • 8.1 Marketing Channel
  • 8.2 Adalimumab, Infliximab And Etanercept Biosimilars Distributors List
  • 8.3 Adalimumab, Infliximab And Etanercept Biosimilars Customers

9 Market Dynamics

  • 9.1 Market Trends
  • 9.2 Opportunities and Drivers
  • 9.3 Challenges
  • 9.4 Porter's Five Forces Analysis

10 Global Market Forecast

  • 10.1 Global Adalimumab, Infliximab And Etanercept Biosimilars Market Estimates and Projections by Product
    • 10.1.1 Global Forecasted Sales of Adalimumab, Infliximab And Etanercept Biosimilars by Product (2021-2026)
    • 10.1.2 Global Forecasted Revenue of Adalimumab, Infliximab And Etanercept Biosimilars by Product (2021-2026)
  • 10.2 Adalimumab, Infliximab And Etanercept Biosimilars Market Estimates and Projections by End Users
    • 10.2.1 Global Forecasted Sales of Adalimumab, Infliximab And Etanercept Biosimilars by End Users (2021-2026)
    • 10.2.2 Global Forecasted Revenue of Adalimumab, Infliximab And Etanercept Biosimilars by End Users (2021-2026)
  • 10.3 Adalimumab, Infliximab And Etanercept Biosimilars Market Estimates and Projections by Region
    • 10.3.1 Global Forecasted Sales of Adalimumab, Infliximab And Etanercept Biosimilars by Region (2021-2026)
    • 10.3.2 Global Forecasted Revenue of Adalimumab, Infliximab And Etanercept Biosimilars by Region (2021-2026)

11 Research Finding and Conclusion

    12 Methodology and Data Source

    • 12.1 Methodology/Research Approach
      • 12.1.1 Research Programs/Design
      • 12.1.2 Market Size Estimation
      • 12.1.3 Market Breakdown and Data Triangulation
    • 12.2 Data Source
      • 12.2.1 Secondary Sources
      • 12.2.2 Primary Sources
    • 12.3 Author List

    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2015 to 2026. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

    Segment by Product, the Adalimumab, Infliximab And Etanercept Biosimilars market is segmented into
    Adalimumab Biosimilars
    Infliximab Biosimilars
    Etanercept Biosimilars

    Segment by End Users
    Hospital Pharmacies
    Retail Pharmacies
    Online Pharmacies

    Global Adalimumab, Infliximab And Etanercept Biosimilars Market: Regional Analysis
    The Adalimumab, Infliximab And Etanercept Biosimilars market is analysed and market size information is provided by regions (countries). The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Product and by End Users segment in terms of sales and revenue for the period 2015-2026.
    The key regions covered in the Adalimumab, Infliximab And Etanercept Biosimilars market report are:
    North America
    U.S.
    Canada
    Europe
    Germany
    France
    U.K.
    Italy
    Russia
    Asia-Pacific
    China
    Japan
    South Korea
    India
    Australia
    Taiwan
    Indonesia
    Thailand
    Malaysia
    Philippines
    Vietnam
    Latin America
    Mexico
    Brazil
    Argentina
    Middle East & Africa
    Turkey
    Saudi Arabia
    U.A.E

    Global Adalimumab, Infliximab And Etanercept Biosimilars Market: Competitive Analysis
    This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2015 to 2019.

    The major players in global Adalimumab, Infliximab And Etanercept Biosimilars market include:
    Boehringer Ingelheim
    Abbvie
    Cipla Ltd
    Hetero Drugs Limited
    Pfizer
    Novartis
    Samsung Bioepis(Samsung Biologics)
    Amgen
    Celltrion Healthcare
    Mylan
    HETERO
    Glenmark Pharmaceuticals
    Emcure Pharmaceuticals


    Summary:
    Get latest Market Research Reports on Adalimumab, Infliximab And Etanercept Biosimilars. Industry analysis & Market Report on Adalimumab, Infliximab And Etanercept Biosimilars is a syndicated market report, published as Global Adalimumab, Infliximab And Etanercept Biosimilars Market Outlook 2021. It is complete Research Study and Industry Analysis of Adalimumab, Infliximab And Etanercept Biosimilars market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

    Last updated on

    REPORT YOU MIGHT BE INTERESTED

    Purchase this Report

    $2,900.00
    $4,350.00
    $5,800.00
    2,132.45
    3,198.67
    4,264.89
    2,396.61
    3,594.91
    4,793.22
    301,150.50
    451,725.75
    602,301.00
    212,172.99
    318,259.49
    424,345.98
    Credit card Logo

    Related Reports


    Reason to Buy

    Request for Sample of this report